Introduction {#Sec1}
============

The autoimmune process in Type 1 Diabetes (T1D) may be a late response to a dysregulation in the metabolism of lipids and amino acids \[[@CR1]--[@CR4]\]. The DIPP (Diabetes Prediction and Prevention Project) and BABYDIAB (a German prospective study from birth on the natural history of type 1 diabetes) studies found reduced levels of methionine and glutamine before islet autoanibody seroconversion in individuals that developed T1D later in life. Oresic et al. also demonstrated decreased levels of phospholipids and triglycerides in the pre-clinical period of T1D \[[@CR2], [@CR3]\].

The amino acids and lipids play an important role in regulating β cells insulin secretion. Glutamine, the most abundant amino acid in blood, presents antioxidant properties, protecting β cells from oxidative insults. Besides, phospholipids may also be a key modulator of insulin release. Therefore, it would be of general importance to identify metabolic patterns that would predict the risk for T1D later in life \[[@CR4]--[@CR6]\].

As most investigations in this field have included only Caucasians, very little is known about the natural history of T1D in other ethnic groups, such as the Brazilian population. It is possible that different populations present peculiarities in the development of T1D. Therefore, it is important to identify if the same metabolic alterations occur in non-Caucasian individuals. This was the first study that analyzed the metabolic profile of FDR of patients with T1D in a multiethnic population.

We aimed to perform a prospective evaluation of glutamine and phospholipids levels in Brazilian FDR of patients with T1D in a mean interval of 5 years.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

First degree relatives (FDR) of Brazilian patients with T1D (*n* = 30, baseline sample) were interviewed and blood was sampled for DNA extraction, metabolites and autoantibody measurement. Participants were classified as whites or non-whites (mostly Afro-descendants) based on their phenotype and family background \[[@CR7]\]. The results from metabolites were compared to non-diabetic controls (*n* = 20).

Measurement of metabolites {#Sec4}
--------------------------

The quantitative colorimetric assays for glutamine and phospholipids measurement were performed at the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. The metabolites were measured in fasting serum of FDR and in control group by quantitative colorimetric method (EnzyChrom Assay Kit of Bioassay Systems). Since the reference range for these tests have not been defined, the frequency of individuals above and below the 50th percentile (p50) obtained in the healthy controls was investigated.

Measurement of autoantibodies {#Sec5}
-----------------------------

Antibodies against GAD, insulin and insulinoma-associated antigen-2 (GADA, IAA and IA2A, respectively) were measured by radioimmunoassay (RIA) \[[@CR8]--[@CR11]\].

Serum samples were also analyzed by a standard radioligand binding assay (RBA) for the three individual ZnT8A variants (ZnT8RA, ZnT8WA, ZnT8QA) as well as with the ZnT8TripleA assay, as previously reported \[[@CR8], [@CR11]\].

Genetic analysis {#Sec6}
----------------

The FDR were genotyped for INS gene and PTPN22 polymorphisms. SNP for INS and PTPN22 (polymorphism RS620W rs2476601) were genotyped with fluorogenic allele-discrimination chemistry \[[@CR12]--[@CR14]\].

Prospective evaluation {#Sec7}
----------------------

After 5 years (a mean interval of 3.8 to 6.3 years), the measurement of glutamine, phospholipids and autoantibodies was repeated. The same technique described above was used.

Statistical analysis {#Sec8}
--------------------

Mann--Whitney *U* test and chi-square were used for comparison between groups. Spearman coefficient was used to test correlation between continuous variables, and Fisher's exact *t*-test to test correlation between categorical variables. A p-value \<0.05 was considered significant. The software applied was SPSS for Windows, version 17.0 (SPSS Inc.)

Results {#Sec9}
=======

The general characteristics of the sample are summarized in Table [1](#Tab1){ref-type="table"}.Table 1General characteristics of the study sampleBasalProspectiveControls*p* valueFDR*FDR*(*n* = 30)(*n* = 30)(*n* = 20)Age (years)17.9617.3625.600.108(mean ± SD)±9.24±8.68±9.65Gender \[n (%)\]Female15 (50)15 (50)9 (45)0.184Etnicity\[n (%)\]Whites15 (50)15 (50)8 (40)0.272Non-whites15 (50)15 (50)12 (60)GADA \[n (%)\]2 (7)2 (7)2 (10)0.887IA2A \[n (%)\]2 (7)1 (3)0*\-\-\--*IAA \[n (%)\]01 (3)0*\-\-\--*ZnT8A \[n (%)\]1 (3)1 (3)00.002Glutamine (mM) (mean ± SD)1.45 ± 0.691.34 ± 0.201.55 ± 0.270.075Phospholipids (μm) (mean ± SD)505.20 ± 194.89468.56 ± 219.46640.00 ± 259.200.028Basal FDR = sample of the basal period; Prospective FDR = sample of the prospective periodControls = non-diabetic individuals; SD = standard deviation; GADA = Glutamic acid decarboxylase autoantibody; IA2A = Insulinoma-associated antigen-2 autoantibody; IAA = autoantibody against insulin; ZnT8A = Zinc transporter 8 autoantibody

Glutamine levels {#Sec10}
----------------

The mean levels of glutamine found in FDR and controls are shown in Table [1](#Tab1){ref-type="table"}. There was no significant variation in the levels of this metabolite in a period of 5 years (*p* = 0.075) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Glutamine levels (mM) in basal sample, prospective sample and controls. The Glutamine levels did not differ between these three groups (*p* = 0.075)

The majority of the FDR presented glutamine levels below the 50th percentile in relation to the median of the control group (23 % or 71.9 % in the baseline sample and 26 % or 86.7 % in the prospective sample), but the difference between these groups was not significant (*p* = 0.075). There was no association between glutamine levels and positive titers of antibodies (*p* = 1.000).

Phospholipids levels {#Sec11}
--------------------

The mean levels of phospholipids found in FDR and controls are shown in Table [1](#Tab1){ref-type="table"}. There was a significant variation in the levels of this metabolite in a period of 5 years (*p* = 0.028) (Fig. [2](#Fig2){ref-type="fig"}). The majority of the FDR showed phospholipids levels below the 50th percentile in relation to the median of the control group (21 % or 65.6 % in the baseline sample and 24 % or 80 % in the prospective sample), with a significant difference between these groups (*p* = 0.028). There was a significant association between low phospholipids levels, positive titers of GADA (*p* = 0.045) in FDR at baseline, and between positivity for autoantibody (GADA) (*p* = 0.008) in the prospective evaluation.Fig. 2Phospholipids levels (μm) in basal sample, prospective sample and controls. The prospective group showed diminished levels of phospholipids in relation to the basal samples and controls (*p* = 0.028)

Genetic polymorphisms {#Sec12}
---------------------

For PTPN22, the prevalence of homozygous was 93.3 % and heterozygous was 6.7 %. None of the FDR presented homozygous T/T for rs24766001 polymorphism of PTPN22.

In the prospective evaluation, there was a significant association between PTPN22 polymorphisms and low phospholipids levels (*p* = 0.014).

The prevalence of rs689 polymorphism of the insulin gene was: homozygous at 43.3 %, heterozygous 40 % or homozygous at 16.7 % . There were no significant differences between polymorphisms of the insulin gene and autoantibodies or metabolites.

Discussion and conclusions {#Sec13}
==========================

In this study we found a significant decrease in phospholipids levels in FDR of patients with T1D during a 5-year prospective follow-up, as well as a significant association between low levels of this metabolite, GADA and PTPN22 polymorphisms. In this study population, most of the FDR presented lower levels of phospholipids in comparison to the control group, similar to the findings in the BABYDIAB cohort. Although the majority of FDR had low glutamine levels, there was no significant difference in comparison with controls. A positive correlation between phospholipids levels, positivity for autoantibody and titers of GADA was found. The altered levels of glutamine, phospholipids, and other metabolites in children at high risk for T1D, before the seroconversion of pancreatic autoantibodies have been repported \[[@CR2], [@CR3]\]. This dysregulation in the metabolism of lipids may be an early marker of autoimmunity, but it still remains unclear if these individuals with low phospholipids levels will have a higher risk of developing T1D \[[@CR4]--[@CR6]\].

The presence of the polymorphic C allele was strongly associated with low levels of phospholipids. Previous studies have shown that polymorphisms of this gene increases the risk of autoimmune diseases emergence by acting in the immunoregulation \[[@CR12]--[@CR20]\]. To our knowledge, the association between PTPN22 polymorphisms and metabolites has not been reported in the literature. This finding may represent a peculiarity of our multiethnic population and further studies in other ethnic groups are necessary.

To conclude, our study found reduced levels of metabolites in FDR of T1D patients, and a positive association between phospholipids, GADA and PTPN22. Some of these results may represent uniqueness of our multiethnic population, while others peculiarities may be common to other populations with T1D. These findings could support further understanding of the pathogenesis of T1D, as well as in stratification of individuals at risk of developing T1D and, contributing to prevention strategies.
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